NEW YORK, April 28, 2014 /PRNewswire/
-- ConvergeHEALTH by Deloitte is announcing that Forest
Laboratories, Inc. (NYSE: FRX), a leading, fully integrated,
specialty pharmaceutical company, and Intermountain Healthcare have
entered into a multi-year collaboration to conduct outcomes
research leveraging a next generation platform for generating
insights into what works for patients. The initial focus of
the collaboration is on respiratory disease.
Forest will be part of a collaborative rapid learning network
created by Intermountain Healthcare and ConvergeHEALTH that
leverages OutcomesMiner, an analytics solution designed to
accelerate the development of new treatments, create better
therapeutic products and improve patient outcomes while taking
costs out of healthcare delivery.
"At ConvergeHEALTH we believe that the shift to value based,
personalized healthcare is a team sport that not only requires
technology and scientific innovation, but new networked R&D
models that support a rapid learning healthcare system, all for the
benefit of patients," said Brett
Davis, principal, Deloitte Consulting LLP and general
manager of ConvergeHEALTH. "We look forward to Forest joining
the ConvergeHEALTH rapid learning network to support this aim as
part of a multi-year collaboration with Intermountain
Healthcare."
Dr. Gavin Corcoran, executive
vice president, medical affairs, health economics and outcomes
research and patient safety at Forest, said "we are excited to work
with Intermountain as part of ConvergeHEALTH by Deloitte's rapid
learning network. Intermountain Healthcare has long been a leader
in leveraging electronic health information to drive unnecessary
variation out of care, while keeping quality high and costs
low."
"This aligns with Forest's vision of collaborative research with
institutes like Intermountain Healthcare enabled by next generation
tools like OutcomesMiner, which provides a platform to conduct real
world research and insights into patient care," said Dr.
Shailja Dixit, executive director,
health economics and outcomes research at Forest. "In
particular, we believe this collaboration has the potential to
provide unique insights into respiratory disease, which will help
optimize use of the appropriate treatment for better patient
outcomes."
Leveraging electronic medical records data, OutcomesMiner will
help Forest understand associated outcomes for treatments and
filter for sub-populations using phenotypic characteristics and
specific medical associations. The solution draws upon
Intermountain's vast repository of electronic health data in
supporting analysis around patient and product outcomes under a
double-blinded format designed to protect the privacy of personal
health information. As part of the collaboration, Forest can
engage with Intermountain's Homer Warner Center for Informatics
Research in conducting institutional review board approved
follow-on studies to support comparative effectiveness research
programs, new product planning activities, health economic and
outcomes research and observational insights that support safety
analytics and decision making. The Homer Warner Center for
Informatics Research is a research facility dedicated to the
discovery and implementation of innovative information technologies
and leveraging Intermountain's data for the improvement of clinical
care.
"We are excited to work with Forest to tackle important
scientific questions that can be best answered by leveraging
informatics techniques and real-world evidence from electronic
medical records," said Dr. Peter
Haug, director of the Homer Warner Center for Informatics
Research at Intermountain Healthcare. "Our goal is to
continue to improve our ability to understand the healthcare needs
of our patients and to provide critical insights into the processes
of care delivery necessary to optimize outcomes for patients
globally."
Greg Reh, principal, Deloitte
Consulting LLP and U.S. leader of Deloitte Consulting's life
sciences practice, said that "by bringing together our leading
clients with analytics and research we've created together, we are
creating a quantum leap in the ability to provide services that
address the heart of the business of what our clients need, deliver
quality studies, analytics and analysis to understand what works in
healthcare."
ConvergeHEALTH will be co-presenting with Forest and
Intermountain Healthcare at the Medical Informatics World
Conference, April 28-29 in
Boston.
About Forest Laboratories
Forest Laboratories, Inc. (NYSE:FRX) is a leading, fully
integrated, specialty pharmaceutical company largely focused on
the United States market. The
company markets a portfolio of branded drug products and develops
new medicines to treat patients suffering from diseases principally
in the following therapeutic areas: central nervous system,
cardiovascular, gastrointestinal, respiratory, anti-infective, and
cystic fibrosis. Our strategy of acquiring product rights for
development and commercialization through licensing, collaborative
partnerships, and targeted mergers and acquisitions allows us to
take advantage of attractive late-stage development and commercial
opportunities, thereby managing the risks inherent in drug
development. The company is headquartered in New York. To learn more, visit
www.FRX.com.
About Intermountain Healthcare
Intermountain Healthcare is a Utah-based not-for-profit system of 22
hospitals, 185 clinics, a Medical Group with about 1,300
employed physicians, a health plans division called SelectHealth,
and other health services. Intermountain is widely recognized as a
leader in transforming healthcare through high quality and
sustainable costs. For more information about Intermountain,
visit www.intermountainhealthcare.org.
About ConvergeHEALTH
ConvergeHEALTH brings powerful, proven analytics platforms and
data models from Recombinant, advanced proprietary and open source
analytics, content and benchmarks from associations with industry
leaders and expertise from Deloitte's life sciences and health care
consulting practice to help our clients thrive in the new paradigm
of value-based, personalized medicine. For more information,
visit www.converge-health.com.
As used in this document, "Deloitte" means Deloitte LLP and its
subsidiaries. Please see www.deloitte.com/us/about for a detailed
description of the legal structure of Deloitte LLP and its
subsidiaries. Certain services may not be available to attest
clients under the rules and regulations of public accounting.
Copyright © 2014 Deloitte Development LLC. All rights
reserved.
Logo -
http://photos.prnewswire.com/prnh/20120803/MM52028LOGO-a
SOURCE Deloitte